

previously performed by the Interstate Commerce Commission, exercises broad authority over transportation by rail carriers, including regulation of railroad rates and service (49 U.S.C. 10701–10747, 11101–11124), as well as the construction, acquisition, operation, and abandonment of rail lines (49 U.S.C. 10901–10907) and railroad line sales, consolidations, mergers, and common control arrangements (49 U.S.C. 10902, 11323–11327).

The Board views the reliability of the nation's energy supply as crucial to this nation's economic and national security, and the transportation by rail of coal and other energy resources as a vital link in the energy supply chain. The Board will hold a public hearing, as a forum for interested persons to provide views and information about issues relating to the efficiency and reliability of rail transportation of resources critical to the nation's energy supply.

*Date of Hearing.* The hearing will begin at 9 a.m. on Wednesday, July 18, 2007 in the Ground Floor Conference Room of the Richard Bolling Federal Building, 601 East 12th Street, Kansas City, MO 64106, and will continue, with breaks as necessary, until every person scheduled to speak has been heard. The Richard Bolling Federal Building is open Monday through Friday from 6 a.m. to 6 p.m. All employees and visitors must present a valid form of photo identification and pass screening before being granted access into the building. Visitors will have access to public areas only.

*Notice of Intent To Participate.* Any person wishing to speak at the hearing should file with the Board a written notice of intent to participate, and should identify the party, the proposed speaker, the time requested, and topic(s) to be covered, as soon as possible, but no later than June 19, 2007.

*Testimony.* Each speaker should file with the Board his/her written testimony by July 5, 2007. Also, any interested person who wishes to submit a written statement without appearing at the July 18 hearing should file that statement by July 5, 2007. If a party intends to use audio-visual materials at the hearing, those materials should be submitted to the Board in electronic form by July 13, 2007.

*Board Releases and Live Audio Available Via the Internet.* Decisions and notices of the Board, including this notice, are available on the Board's Web site at <http://www.stb.dot.gov>. Information concerning the availability of live audio streaming of this hearing will be included in the decision scheduling speaker times.

This action will not significantly affect either the quality of the human environment or the conservation of energy resources.

Dated: June 6, 2007.

**Vernon A. Williams,**  
Secretary.

[FR Doc. E7–11236 Filed 6–8–07; 8:45 am]

**BILLING CODE 4915–01–P**

## DEPARTMENT OF VETERANS AFFAIRS

### Notice of Intent To Grant an Exclusive License

**AGENCY:** Department of Veterans Affairs, Office of Research and Development.

**ACTION:** Notice of Intent.

**SUMMARY:** Notice is hereby given that the Department of Veterans Affairs, Office of Research and Development, intends to grant to Bioceuticals, Inc., 26439 Birchfield Avenue, Rancho Palos Verdes, CA 90275 USA an exclusive license to practice the following patent application: U.S. Patent Application Serial No. 10/750,005 filed December 30, 2003 entitled "Methods for Reducing Oxidative Stress in a Cell with a Sulfhydryl Protected Glutathione Prodrug."

**DATES:** Comments must be received within fifteen (15) days from the date of this published Notice.

**ADDRESSES:** Send comments to: Amy E. Centanni, Director of Technology Transfer, Department of Veterans Affairs; Office of Research and Development, 810 Vermont Avenue, NW., Washington, DC 20420, Attn: 12TT, Telephone: (202) 254–0199; Facsimile: (202) 254–0460; e-mail: [Amy.centanni@va.gov](mailto:Amy.centanni@va.gov).

**FOR FURTHER INFORMATION CONTACT:** Copies of the published patent applications may be obtained from the U.S. Patent and Trademark Office at <http://www.uspto.gov>.

**SUPPLEMENTARY INFORMATION:** It is in the public interest to so license these inventions as Bioceuticals, Inc. submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within fifteen (15) days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development receives written evidence and argument which establishes that the grant of the license

would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Dated: June 5, 2007.

**Gordon H. Mansfield,**  
Deputy Secretary of Veterans Affairs.

[FR Doc. E7–11223 Filed 6–8–07; 8:45 am]

**BILLING CODE 8320–01–P**

## DEPARTMENT OF VETERANS AFFAIRS

### Notice of Intent To Grant an Exclusive License

**AGENCY:** Department of Veterans Affairs, Office of Research and Development.

**ACTION:** Notice of Intent.

**SUMMARY:** Notice is hereby given that the Department of Veterans Affairs, Office of Research and Development, intends to grant to Perlegen Sciences, Inc., 2021 Stierlin Court, Mountain View, CA 94043 USA an exclusive license to practice the following patent application: U.S. Patent Application Serial No. 11/344,975 filed January 31, 2006 entitled "Genetic Basis of Alzheimer's Disease and Diagnosis and Treatment Thereof."

**DATES:** Comments must be received within fifteen (15) days from the date of this published Notice.

**ADDRESSES:** Send comments to: Amy E. Centanni, Director of Technology Transfer, Department of Veterans Affairs; Office of Research and Development, 810 Vermont Avenue, NW., Washington, DC 20420, Attn: 12TT, Telephone: (202) 254–0199; Facsimile: (202) 254–0460; e-mail: [Amy.centanni@va.gov](mailto:Amy.centanni@va.gov).

**FOR FURTHER INFORMATION CONTACT:** Copies of the published patent applications may be obtained from the U.S. Patent and Trademark Office at <http://www.uspto.gov>.

**SUPPLEMENTARY INFORMATION:** It is in the public interest to so license these inventions as Perlegen Sciences, Inc. submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within fifteen (15) days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.